OneSource, Hikma get approval for generic Ozempic in Saudi Arabia

Core Insights - OneSource Specialty Pharma has received approval from the Saudi Food and Drug Authority (SFDA) for its generic version of Ozempic (semaglutide), enabling commercialization in Saudi Arabia through a partnership with Hikma Pharmaceuticals PLC [1][2] Group 1: Market Entry and Strategy - The approval signifies OneSource's entry into Saudi Arabia, a significant market for GLP-1 therapies, aiming to enhance access to affordable generic alternatives in the region [2] - The partnership with Hikma, the largest pharmaceutical company in the MENA region by sales, is expected to provide a robust platform for scaling access to semaglutide [4] Group 2: Manufacturing and Supply Chain - Under the exclusive agreement, OneSource will manufacture and supply semaglutide from its facility in Bengaluru, while Hikma will utilize its regional reach to expand access through private and institutional channels [3]